Filtered By:
Management: Marketing

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 2013
Presentation of neurological data confirms patients in the device group had fewer, smaller strokes that were less likely to originate from blood clots passing through the PFO ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc... Devices, Interventional CardiologySt. Jude Medical, patent foramen ovale, AMPLATZER, AMPLATZER PFO Occluder
Source: HSMN NewsFeed - February 8, 2013 Category: Pharmaceuticals Source Type: news

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news

Any defence of sugar is pure confection | Aseem Malhotra
More and more people are challenging the food industry's PR machine. The evidence shows that sugar, not fat, is the enemyThe public health minister, Anna Soubry, has commented that the poor are more likely to be obese. It is well known that social status is linked to health, but her comments were also motivated by a mentality that victimises the most vulnerable. She should really be directing her criticism at the food industry. There is no doubt that an oversupply of cheap junk food fuelled by unregulated and irresponsible marketing limits our ability to make healthy choices. But there is an equally important question that...
Source: Guardian Unlimited Science - January 24, 2013 Category: Science Authors: Aseem Malhotra Tags: Comment Food & drink industry Obesity Health guardian.co.uk Health policy Society UK news Life and style Business Science Comment is free Source Type: news

NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE Area: News In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).   The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news